# A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour

> **NCT06888830** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 374 (estimated)

## Conditions studied

- Advanced Malignant Solid Tumours

## Interventions

- **DRUG:** JS212 for Injection

## Key facts

- **NCT ID:** NCT06888830
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-11
- **Primary completion:** 2026-07-01
- **Final completion:** 2027-04-01
- **Target enrollment:** 374 (ESTIMATED)
- **Last updated:** 2025-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06888830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06888830, "A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06888830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*